Semaglutide for NASH: Can a GLP-1 Drug Reverse Fatty Liver Disease?

Semaglutide and Liver Disease: A New Therapeutic Frontier

Non-alcoholic steatohepatitis (NASH), now increasingly referred to as metabolic dysfunction-associated steatohepatitis (MASH), is one of the most prevalent chronic liver diseases worldwide, affecting an estimated 3-5% of the global population. Despite its prevalence, there are very few approved pharmacotherapies specifically for NASH. The discovery that semaglutide can resolve NASH in a significant proportion of patients represents one of the most promising developments in hepatology [1].

The Phase 2 NASH Trial (NEJM 2021)

The landmark Phase 2 trial, published in the New England Journal of Medicine in March 2021 by Newsome et al., was the first randomized controlled trial to evaluate semaglutide specifically for NASH treatment [1].

Study Design:

• 320 patients with biopsy-confirmed NASH (fibrosis stages F1-F3)
• Randomized to once-daily subcutaneous semaglutide (0.1 mg, 0.2 mg, or 0.4 mg) or placebo
• Treatment duration: 72 weeks
• Primary endpoint: Resolution of NASH without worsening of fibrosis
• Key secondary endpoint: Improvement in fibrosis without worsening of NASH

NASH Resolution Results:

• Semaglutide 0.1 mg: 40% achieved NASH resolution
• Semaglutide 0.2 mg: 36%
• Semaglutide 0.4 mg: 59% achieved NASH resolution
• Placebo: 17%
• Odds ratio for 0.4 mg vs. placebo: 6.87 (95% CI, 2.60-17.63; P<0.001)

Fibrosis Results:

• Improvement in fibrosis stage (≥1 stage): 43% with semaglutide 0.4 mg vs. 33% with placebo
• This difference was not statistically significant (P=0.48)
• Worsening of fibrosis: 5% with semaglutide 0.4 mg vs. 19% with placebo

The disconnect between impressive NASH resolution and modest fibrosis improvement became a key discussion point in the hepatology community [1].

Understanding the Histological Findings

The liver biopsy data revealed nuanced effects of semaglutide on liver histology:

NAS (NAFLD Activity Score) Improvements:

• Mean NAS improvement was significantly greater with semaglutide across all doses
• Improvements were seen in all three NAS components: steatosis, lobular inflammation, and hepatocyte ballooning
• The most dramatic improvement was in steatosis (fat content), consistent with semaglutide's metabolic effects

Liver Enzyme Improvements:

• ALT (alanine aminotransferase): Significant reductions with semaglutide
• AST (aspartate aminotransferase): Significant reductions
• GGT (gamma-glutamyl transferase): Significant reductions
• These biochemical improvements correlated with histological improvement [1].

The Cirrhosis Trial (Lancet 2023)

A separate Phase 2 trial evaluated semaglutide in patients with NASH and compensated cirrhosis (fibrosis stage F4), published in The Lancet Gastroenterology & Hepatology in 2023 by Loomba et al. [2].

Key Findings:

• 71 patients with NASH-related compensated cirrhosis
• Semaglutide 2.4 mg once weekly vs. placebo for 48 weeks
• NASH resolution without worsening fibrosis: 26.2% semaglutide vs. 9.7% placebo
• Fibrosis improvement (≥1 stage): Not significantly different from placebo
• No worsening of hepatic or renal function

The cirrhosis trial results were more modest than the non-cirrhotic trial, suggesting that semaglutide may be more effective in earlier stages of liver disease before irreversible fibrotic changes occur [2].

Mechanisms of Hepatoprotection

Semaglutide's beneficial effects on the liver appear to involve multiple mechanisms:

1. Weight loss and metabolic improvement: Reducing adiposity decreases hepatic fat delivery and improves insulin resistance, the primary driver of NASH.

2. Direct hepatic effects: GLP-1 receptors are expressed on hepatocytes, and GLP-1 receptor activation may directly reduce hepatic lipogenesis and inflammation.

3. Anti-inflammatory effects: Semaglutide reduces systemic inflammation (as measured by CRP), which may contribute to reduced hepatic inflammation.

4. Improved lipid metabolism: Enhanced fatty acid oxidation and reduced de novo lipogenesis in the liver.

Non-Invasive Biomarker Data

The NASH trials also evaluated non-invasive biomarkers that could be used to monitor treatment response without repeated liver biopsies:

• FibroScan (liver stiffness): Improved with semaglutide treatment
• MRI-PDFF (liver fat fraction): Dramatically reduced, correlating with histological steatosis improvement
• FIB-4 index: Improved, suggesting reduced fibrosis burden
• Enhanced Liver Fibrosis (ELF) score: Modest improvements

These biomarker findings support the development of non-invasive monitoring strategies for semaglutide-treated NASH patients [1].

Ongoing Phase 3 Development

Based on the Phase 2 results, Novo Nordisk launched the ESSENCE Phase 3 program evaluating semaglutide 2.4 mg for NASH:

• ESSENCE trial: Large-scale Phase 3 trial in non-cirrhotic NASH patients
• Primary endpoints include NASH resolution and fibrosis improvement
• Results are expected to support potential regulatory approval for NASH indication
• If successful, semaglutide could become one of the first approved pharmacotherapies specifically for NASH

Clinical Perspective

The semaglutide NASH data highlights both promise and limitations:

Strengths:

• Impressive NASH resolution rates (59% at highest dose)
• Well-characterized safety profile from extensive obesity/diabetes experience
• Addresses the metabolic root cause of NASH
• Dual benefit for patients with obesity and NASH

Limitations:

• Fibrosis improvement was not statistically significant
• Less effective in advanced (cirrhotic) disease
• Requires ongoing treatment (chronic disease model)
• Cost and access remain barriers for many patients

References

1. Newsome PN, Buchholtz K, Cusi K, et al. "A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis." New England Journal of Medicine. 2021;384(12):1113-1124. PubMed: 33185364

2. Loomba R, Abdelmalek MF, Armstrong MJ, et al. "Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial." The Lancet Gastroenterology & Hepatology. 2023;8(6):511-522. PubMed: 36934740